FDA OKs lumateperone, accelerated deep TMS for MDD

The U.S. Food and Drug Administration (FDA) has recently announced two significant advances in the treatment of major depressive disorder (MDD), a condition affecting millions of adults nationwide. These developments expand therapeutic options for patients who continue to struggle despite standard antidepressant therapy.